AgeTech is growing. We speak with an expert

Lorraine Morley from Allia

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The AgeTech sector is growing fast and the venture capital sector is starting to pay attention; where are the opportunities and risks?

New technology seems to be around every corner you look, from AI speakers to health apps, technology is evolving at an accelerating pace. However, coupled with the predicted ‘silver tsunami’, these two trends are coming together to create a booming AgeTech market. The European Commission expects the AgeTech market to hit $8.5 trillion in Europe alone by 2025 [1]. With the surge of interest in this growing field, investors are tuning in closer than before.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Seragy raises $13.4m for protein clumps

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE